Join
Live feed
·
NEWSReleasevia Quantisnow
NanoViricides Inc. logo

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

ByQuantisnow·Wall Street's wire, on your screen.
NNVC· NanoViricides Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NNVC (NanoViricides Inc.) and more on Quantisnow.